These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 32930131)
1. Neo-adjuvant chemotherapy followed by either continuous hyper-fractionated accelerated radiation therapy week-end less or conventional chemo-radiotherapy in locally advanced NSCLC-A randomised prospective single institute study. Kumar R; Kumar HS; Paramanandhan M; Purohit R; Sharma N; Jakhar SL; Sharma S; Maharia S; Rai RK J Cancer Res Ther; 2020; 16(4):860-866. PubMed ID: 32930131 [TBL] [Abstract][Full Text] [Related]
2. Dose-escalation with CHARTWEL (continuous hyperfractionated accelerated radiotherapy week-end less) combined with neo-adjuvant chemotherapy in the treatment of locally advanced non-small cell lung cancer. Saunders MI; Rojas A; Lyn BE; Wilson E; Phillips H Clin Oncol (R Coll Radiol); 2002 Oct; 14(5):352-60. PubMed ID: 12555873 [TBL] [Abstract][Full Text] [Related]
3. Randomized phase I study of standard-fractionated or accelerated-hyperfractionated radiotherapy with concurrent cisplatin and vindesine for unresectable non-small cell lung cancer: a report of Japan Clinical Oncology Group Study (JCOG 9601). Tsuchiya S; Ohe Y; Sugiura T; Fuwa N; Kitamoto Y; Mori K; Kobayashi H; Nakata K; Sawa T; Hirai K; Etoh T; Saka H; Saito A; Fukuda H; Ishizuka N; Saijo N; Jpn J Clin Oncol; 2001 Oct; 31(10):488-94. PubMed ID: 11696618 [TBL] [Abstract][Full Text] [Related]
4. How to improve loco-regional control in stages IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group. Nyman J; Friesland S; Hallqvist A; Seke M; Bergström S; Thaning L; Lödén B; Sederholm C; Wagenius G Lung Cancer; 2009 Jul; 65(1):62-7. PubMed ID: 19081652 [TBL] [Abstract][Full Text] [Related]
5. High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study. Liu YE; Lin Q; Meng FJ; Chen XJ; Ren XC; Cao B; Wang N; Zong J; Peng Y; Ku YJ; Chen Y Radiat Oncol; 2013 Aug; 8(1):198. PubMed ID: 23937855 [TBL] [Abstract][Full Text] [Related]
6. Continuous hyperfractionated accelerated radiotherapy - Escalated dose (CHART-ED): A phase I study. Hatton MQ; Hill R; Fenwick JD; Morgan SA; Wilson PC; Atherton PJ; Dickson J; Murray KE; Paul J Radiother Oncol; 2016 Mar; 118(3):471-7. PubMed ID: 26687902 [TBL] [Abstract][Full Text] [Related]
7. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. Belani CP; Wang W; Johnson DH; Wagner H; Schiller J; Veeder M; Mehta M; J Clin Oncol; 2005 Jun; 23(16):3760-7. PubMed ID: 15837967 [TBL] [Abstract][Full Text] [Related]
8. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group. Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975 [TBL] [Abstract][Full Text] [Related]
9. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). Baumann M; Herrmann T; Koch R; Matthiessen W; Appold S; Wahlers B; Kepka L; Marschke G; Feltl D; Fietkau R; Budach V; Dunst J; Dziadziuszko R; Krause M; Zips D; Radiother Oncol; 2011 Jul; 100(1):76-85. PubMed ID: 21757247 [TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy followed by late-course accelerated hyperfractionated radiation therapy for locally advanced non-small-cell lung cancer: long-term results of a phase I/II clinical trial. Chen M; Chen YY; Bao Y; Xian CG; Liu GZ; Zhang L; Xu GC; Deng XW; Lu TX; Qian JY; Cui NJ Clin Lung Cancer; 2005 Mar; 6(5):304-9. PubMed ID: 15845182 [TBL] [Abstract][Full Text] [Related]
11. Experience with dose escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekend less) in non-small-cell lung cancer. Saunders MI; Rojas A; Lyn BE; Pigott K; Powell M; Goodchild K; Hoskin PJ; Phillips H; Verma N Br J Cancer; 1998 Nov; 78(10):1323-8. PubMed ID: 9823973 [TBL] [Abstract][Full Text] [Related]
12. Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04. Komaki R; Seiferheld W; Ettinger D; Lee JS; Movsas B; Sause W Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):548-57. PubMed ID: 12062596 [TBL] [Abstract][Full Text] [Related]
13. Induction chemotherapy followed by concurrent chemotherapy and definitive high-dose radiotherapy for patients with locally advanced non-small-cell lung cancer (stages IIIa/IIIb): a pilot phase I/II trial. Pöttgen C; Eberhardt W; Bildat S; Stüben G; Stamatis G; Hillejan L; Sohrab S; Teschler H; Seeber S; Sack H; Stuschke M Ann Oncol; 2002 Mar; 13(3):403-11. PubMed ID: 11996471 [TBL] [Abstract][Full Text] [Related]
14. Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer. Lee SW; Choi EK; Lee JS; Lee SD; Suh C; Kim SW; Kim WS; Ahn SD; Yi BY; Kim JH; Noh YJ; Kim SS; Koh Y; Kim DS; Kim WD Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):996-1004. PubMed ID: 12829135 [TBL] [Abstract][Full Text] [Related]
15. Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group. Komaki R; Scott CB; Sause WT; Johnson DH; Taylor SG; Lee JS; Emami B; Byhardt RW; Curran WJ; Dar AR; Cox JD Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):537-44. PubMed ID: 9336129 [TBL] [Abstract][Full Text] [Related]
16. Toxicity and outcome of a phase II trial of taxane-based neoadjuvant chemotherapy and 3-dimensional, conformal, accelerated radiotherapy in locally advanced nonsmall cell lung cancer. Rojas AM; Lyn BE; Wilson EM; Williams FJ; Shah N; Dickson J; Saunders MI Cancer; 2006 Sep; 107(6):1321-30. PubMed ID: 16902985 [TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant etoposide, ifosfamide, and cisplatin followed by concomitant thoracic radiotherapy and continuous cisplatin infusion in stage IIIb non-small cell lung cancer. Pujol JL; Lafontaine T; Quantin X; Reme-Saumon M; Cupissol D; Khial F; Michel FB Chest; 1999 Jan; 115(1):144-50. PubMed ID: 9925076 [TBL] [Abstract][Full Text] [Related]
18. Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemo-radiotherapy in stage III non-small cell lung cancer: final results of an international phase II trial. Krzakowski M; Provencio M; Utracka-Hutka B; Villa E; Codes M; Kuten A; Henke M; Lopez M; Bell D; Biti G; Merimsky O; Beorchia A; Riggi M; Caux NR; Pouget JC; Dubray B; David P J Thorac Oncol; 2008 Sep; 3(9):994-1002. PubMed ID: 18758302 [TBL] [Abstract][Full Text] [Related]
19. Accelerated hyperfractionated radiotherapy combined with induction and concomitant chemotherapy for inoperable non-small-cell lung cancer--impact of total treatment time. Nyman J; Bergman B; Mercke C Acta Oncol; 1998; 37(6):539-45. PubMed ID: 9860311 [TBL] [Abstract][Full Text] [Related]
20. Dose escalation of accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in unresectable stage III non-small-cell lung cancer: a phase I trial. Lin Q; Liu YE; Ren XC; Wang N; Chen XJ; Wang DY; Zong J; Peng Y; Guo ZJ; Hu J Radiat Oncol; 2013 Aug; 8(1):201. PubMed ID: 23957889 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]